Insulin SensitivityNCT02870088
The Effect of Breaking Prolonged Sitting on Adipose Tissue and Metabolism
A study testing Prolonged Sitting and Breaking Sitting in people with Insulin Sensitivity, run by University of Bath.
Trial summary
The purpose of this project is to investigate the effect of breaking prolonged sitting on acute adipose tissue and metabolic responses. Read more about this study
- Who is it for?
- Ages 35 to 64 yearsHealthy volunteers can take part
- Conditions the study is for
- Insulin Sensitivity
- What is being tested?
- Prolonged Sitting and Breaking Sitting
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 11 participants
- Where
- No sites listed yet
- Study dates
- Jul 2014to Jan 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 64 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male and post-menopausal females (post-menopausal diagnosis based on consecutive absence of menstrual cycles for >12 months).
- Aged between 35 and 64 years
- Central overweight (waist circumference greater than 94 cm for males and 80 cm for females)
- Weight stable for more than 3 months (no change in weight +/- 3%)
- Non-smoker
- Able to walk comfortably on a treadmill
Who cannot join
- Personal history of/existing diabetes, cardiovascular disease, metabolic disease or dyslipidaemia
- Waist circumference < 94cm for male and < 80cm for female
- Taking medications that may influence lipid or carbohydrate metabolism or immune system function
- Unable to take part in exercise for any reason (e.g., injury or disability) or a positive response to any questions on the Physical Activity Readiness questionnaire (PAR-Q)
About this study
The purpose of this project is to investigate the effect of breaking prolonged sitting on acute adipose tissue and metabolic responses.
Read the detailed description
Pre-trial assessments:
Physical activity assessment : a combined heart rate/accelerometer monitor was worn for 7 days to assess participant's habitual physical activity energy expenditure (Actiheart, Cambridge Neurotechnology Ltd., Cambridge, UK). This was attached to the left chest via 2 adhesive ECG pads for 24 hours per day except for during showering/bathing/swimming.
Body composition analysis:
Body mass was assessed using digital scales post-void (TANITA corp., Tokyo, Japan). Waist and hip circumference was assessed based on World Health Organisation guidelines. Body composition was determined by using Dual energy X-ray absorptiometry (Discovery, Hologic, Bedford, UK). Abdominal subcutaneous and visceral adipose tissue mass was estimated from a central region between L1-L4.
Trial days:
In the 72 h prior to each main trial, participants were asked to refrain from performing any strenuous physical activity. In the 48 h prior to each main trial, consuming alcohol/caffeine was not allowed and in the meantime, a dietary record was completed 48 h before the first main trial. Participants were asked to replicate this diet prior to their second main trial. In addition, in the 48 h prior to each main trial, participants were asked to restrict their steps to under 4000 steps per day in order to mimic sedentary lifestyle patterns and eliminate any acute effects from recent physical activity.
Two trials were performed including one prolonged sitting and one breaking prolonged sitting trials. In the breaking trial, after consuming 1st meal, participants walked 2 min on a treadmill at 6.4 km/h speed every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants were continue 2 min of breaking prolonged sitting physical activity at the same speed every 20 min for the following 120 min. In total, participants performed 15 two minute bouts of physical activity throughout the trial for a total of 30 min breaking prolonged sitting physical activity. In the prolonged sitting trial, participants sat on a chair.
Expired air, RPE and heart rate were collected in two of breaking sitting walks to determine exercise intensity and energy expenditure. In addition, two 5 min sitting of expired air and heart rate were taken to calculated total energy expenditure during sitting. During each trial, participants were allowed to move from a sitting position to the treadmill or to void if required. While sitting, participants were only allowed to read, use a laptop or watch television but were otherwise asked to keep as still as possible throughout. In the first trial, participants were allowed to consume water ad libitum and the volume ingested was replicated for the 2nd trial
In each main trial, baseline blood samples was collected before the 1st meal and hourly for the following 5 hours. Additional blood samples were collected every 15 min after the first and second meal. A total of 14 blood samples were collected for each trial.
Adipose tissue culture and gene expression:
After adipose tissue biopsy and cleaning, tissue was minced to approximately 5-10 mg and directly placed in sterile culture plates (Nunc, Roskilde, Denmark) with endothelial cell basal media (ECBM) containing 0.1% fatty acid-free bovine serum albumin 100 U ml-1 penicillin and 0.1 mg ml-1 streptomycin (Sigma-Aldrich, Gillingham, UK). Adipose tissue was incubated with a final ratio of 100mg tissue per 1 ml ECBM media for 3 hours. A 37°C, 5% CO2 and 95 ± 5% relative humidity incubator was used (MCO-18A1C CO2 incubator; Sanyo, Osaka, Japan). Media was transferred to sterile eppendorfs and stored at -80°C after 3 hours incubation. Approximately 200 mg adipose tissue was homogenised in 5ml Trizol in an RNase/DNase-free sterile tube (Invitrogen, Paisley, UK) and stored at -80°C before further analysis.
Sample size:
A previous similar study reported incremental area under curve (iAUC) for insulin during breaking prolonged sitting compared to prolonged sitting of 3337 IU L-1 9h-1 and 2470 IU L-1 9h-1, respectively. Based on an assumed SD of 600 IU L-1 9h-1, we would require 9 participants to show a difference in iAUC for insulin with 95% power and 5% alpha.
Statistics:
All data was presented as mean ± standard error of mean (SEM). Incremental area under curve (iAUC) was calculated using the trapezoid method and differences between trials analysed using paired t-tests. Glucose, insulin, NEFA, adipokines, and cell culture outcomes were determined using a two-way ANOVA with repeated measures using SPSS version 22 (IBM, Armonk, NY, USA). Where significant interactions (trial × time) were found, a post hoc analysis was applied using t-test with the Holm-Bonferroni correction. Single comparisons used a t-test or non-parametric equivalent. Statistical significance was set at p ≤ 0.05.
- Conditions
- Insulin Sensitivity
- Being tested
- Prolonged Sitting, Breaking Sitting
- Medical subject headings
- Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Prolonged SittingBehavioural
After consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min.
Breaking SittingBehavioural
After consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min.
| Study group | Role | What they receive |
|---|---|---|
| Prolonged Sitting | Active comparator | Participants sat on a chair during the trial. Receives: Behavioral: Prolonged Sitting |
| Breaking Sitting | Experimental | Participants walked regularly during the trial. Receives: Behavioral: Breaking Sitting |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incremental area under curve (iAUC) for insulin
Measured: 330 minutes
Secondary outcomes (4)
Changes in gene expression in the adipose tissue
Measured: Before the 1st meal and 120 min after the 2nd meal (330 minutes).
Changes in insulin, glucose, TAG and NEFA in blood
Measured: 330 minutes
Changes in serum Interleukin-6 (IL-6), leptin and adiponectin
Measured: 330 minutes
Changes in Interleukin-6 (IL-6), leptin and adiponectin protein secretion from adipose tissue explants
Measured: Before the 1st meal and 120 min after the 2nd meal (330 minutes).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2016 (estimated)
- Study startJul 2014
- Primary completionJan 2016
- Study completionJan 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Insulin SensitivityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 11 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Bath
- Sponsor type
- University, hospital or other
- Collaborators
- Ministry of Education, Taiwan
- Responsible party
- Principal investigator, Yung-Chih Chen, University of Bath
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02870088
- Sponsor's protocol ID
- 13/SW/0321
- Status last verified
- Aug 2016
- First submitted
- 9 Feb 2016
- Last updated
- 17 Aug 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Breaking Prolonged Sitting on Adipose Tissue and Metabolism
- ClinicalTrials.gov ID
- NCT02870088
- Acronym / sponsor ID
- 13/SW/0321
- Conditions
- Insulin Sensitivity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 11 participants (actual)
- Lead sponsor
- University of BathUniversity, hospital or other
- Collaborators
- Ministry of Education, Taiwan
- Study start
- Jul 2014
- Primary completion
- Jan 2016 (actual)
- Study completion
- Jan 2016 (actual)
- First posted
- 17 Aug 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this project is to investigate the effect of breaking prolonged sitting on acute adipose tissue and metabolic responses.
Detailed description
Pre-trial assessments:
Physical activity assessment : a combined heart rate/accelerometer monitor was worn for 7 days to assess participant's habitual physical activity energy expenditure (Actiheart, Cambridge Neurotechnology Ltd., Cambridge, UK). This was attached to the left chest via 2 adhesive ECG pads for 24 hours per day except for during showering/bathing/swimming.
Body composition analysis:
Body mass was assessed using digital scales post-void (TANITA corp., Tokyo, Japan). Waist and hip circumference was assessed based on World Health Organisation guidelines. Body composition was determined by using Dual energy X-ray absorptiometry (Discovery, Hologic, Bedford, UK). Abdominal subcutaneous and visceral adipose tissue mass was estimated from a central region between L1-L4.
Trial days:
In the 72 h prior to each main trial, participants were asked to refrain from performing any strenuous physical activity. In the 48 h prior to each main trial, consuming alcohol/caffeine was not allowed and in the meantime, a dietary record was completed 48 h before the first main trial. Participants were asked to replicate this diet prior to their second main trial. In addition, in the 48 h prior to each main trial, participants were asked to restrict their steps to under 4000 steps per day in order to mimic sedentary lifestyle patterns and eliminate any acute effects from recent physical activity.
Two trials were performed including one prolonged sitting and one breaking prolonged sitting trials. In the breaking trial, after consuming 1st meal, participants walked 2 min on a treadmill at 6.4 km/h speed every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants were continue 2 min of breaking prolonged sitting physical activity at the same speed every 20 min for the following 120 min. In total, participants performed 15 two minute bouts of physical activity throughout the trial for a total of 30 min breaking prolonged sitting physical activity. In the prolonged sitting trial, participants sat on a chair.
Expired air, RPE and heart rate were collected in two of breaking sitting walks to determine exercise intensity and energy expenditure. In addition, two 5 min sitting of expired air and heart rate were taken to calculated total energy expenditure during sitting. During each trial, participants were allowed to move from a sitting position to the treadmill or to void if required. While sitting, participants were only allowed to read, use a laptop or watch television but were otherwise asked to keep as still as possible throughout. In the first trial, participants were allowed to consume water ad libitum and the volume ingested was replicated for the 2nd trial
In each main trial, baseline blood samples was collected before the 1st meal and hourly for the following 5 hours. Additional blood samples were collected every 15 min after the first and second meal. A total of 14 blood samples were collected for each trial.
Adipose tissue culture and gene expression:
After adipose tissue biopsy and cleaning, tissue was minced to approximately 5-10 mg and directly placed in sterile culture plates (Nunc, Roskilde, Denmark) with endothelial cell basal media (ECBM) containing 0.1% fatty acid-free bovine serum albumin 100 U ml-1 penicillin and 0.1 mg ml-1 streptomycin (Sigma-Aldrich, Gillingham, UK). Adipose tissue was incubated with a final ratio of 100mg tissue per 1 ml ECBM media for 3 hours. A 37°C, 5% CO2 and 95 ± 5% relative humidity incubator was used (MCO-18A1C CO2 incubator; Sanyo, Osaka, Japan). Media was transferred to sterile eppendorfs and stored at -80°C after 3 hours incubation. Approximately 200 mg adipose tissue was homogenised in 5ml Trizol in an RNase/DNase-free sterile tube (Invitrogen, Paisley, UK) and stored at -80°C before further analysis.
Sample size:
A previous similar study reported incremental area under curve (iAUC) for insulin during breaking prolonged sitting compared to prolonged sitting of 3337 IU L-1 9h-1 and 2470 IU L-1 9h-1, respectively. Based on an assumed SD of 600 IU L-1 9h-1, we would require 9 participants to show a difference in iAUC for insulin with 95% power and 5% alpha.
Statistics:
All data was presented as mean ± standard error of mean (SEM). Incremental area under curve (iAUC) was calculated using the trapezoid method and differences between trials analysed using paired t-tests. Glucose, insulin, NEFA, adipokines, and cell culture outcomes were determined using a two-way ANOVA with repeated measures using SPSS version 22 (IBM, Armonk, NY, USA). Where significant interactions (trial × time) were found, a post hoc analysis was applied using t-test with the Holm-Bonferroni correction. Single comparisons used a t-test or non-parametric equivalent. Statistical significance was set at p ≤ 0.05.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Prolonged Sitting | Active comparator | Behavioral: Prolonged SittingParticipants sat on a chair during the trial. |
| Breaking Sitting | Experimental | Behavioral: Breaking SittingParticipants walked regularly during the trial. |
Who may qualify
- Ages
- 35 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Male and post-menopausal females (post-menopausal diagnosis based on consecutive absence of menstrual cycles for >12 months).
- Aged between 35 and 64 years
- Central overweight (waist circumference greater than 94 cm for males and 80 cm for females)
- Weight stable for more than 3 months (no change in weight +/- 3%)
- Non-smoker
Key exclusion criteria (4 listed)
- Personal history of/existing diabetes, cardiovascular disease, metabolic disease or dyslipidaemia
- Waist circumference < 94cm for male and < 80cm for female
- Taking medications that may influence lipid or carbohydrate metabolism or immune system function
- Unable to take part in exercise for any reason (e.g., injury or disability) or a positive response to any questions on the Physical Activity Readiness questionnaire (PAR-Q)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Prolonged SittingAfter consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min. | Behavioural | Prolonged Sitting |
| Breaking SittingAfter consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min. | Behavioural | Breaking Sitting |
Primary outcome
Incremental area under curve (iAUC) for insulin
Time frame: 330 minutes
4 secondary outcomes
Changes in gene expression in the adipose tissue
Time frame: Before the 1st meal and 120 min after the 2nd meal (330 minutes).
Changes in insulin, glucose, TAG and NEFA in blood
Time frame: 330 minutes
Changes in serum Interleukin-6 (IL-6), leptin and adiponectin
Time frame: 330 minutes
Changes in Interleukin-6 (IL-6), leptin and adiponectin protein secretion from adipose tissue explants
Time frame: Before the 1st meal and 120 min after the 2nd meal (330 minutes).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2016.
- Individual participant dataSharing planned: Undecided
Related trials for Insulin Sensitivity
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Not yet recruitingPhase 2
Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity
Insulin Resistance, Obesity
Recruiting
Improving Sleep Health and Circadian Timing to Support Cardiometabolic Health in Adolescents
Overweight Adolescents, Sleep
Not yet recruitingObservational study
Clinical Research Trial to Study Insulin Sensitivity Using Automated Glucose Clamp Technology
Obesity Type 2 Diabetes Mellitus, Obese Adults
Not yet recruiting
Effects of Mango on Insulin Sensitivity in Prediabetes
Pre Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Prolonged Sitting and Breaking Sitting in people with Insulin Sensitivity, run by University of Bath.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Aug 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incremental area under curve (iAUC) for insulin (time frame: 330 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2016.